Recent results from Total Therapy Study X for standard and high risk acute lymphoblastic leukemia in children: recognition of new clinical and biologic risk features.

Abstract

The initiation of Total Therapy Study X in 1979 marked important new directions for leukemia studies at St. Jude, since for the first time treatment for Standard and high risk forms of lymphoblastic leukemia differed radically. Furthermore, recognizing the heterogeneity of childhood ALL, the blast cell characteristics of each new patient were prospectively investigated by Standard methods [1–3], and the independent impact of various clinical and biologic features on the outcome of therapy was thoroughly investigated. This report will present highlights of our recent results.